-
Annals of Clinical Psychiatry :... Sep 1995This paper reports the coocurrence of paranoid psychosis and acute lymphocytic leukemia in a 16-year-old African-American male. Subsequently, he developed a neuroleptic... (Review)
Review
This paper reports the coocurrence of paranoid psychosis and acute lymphocytic leukemia in a 16-year-old African-American male. Subsequently, he developed a neuroleptic malignant-like syndrome and several other ill-defined complications of antipsychotic therapy, which presented difficult management problems for the medical and psychiatric staff caring for him. Definitive treatment for his psychiatric disorder (ECT) involved possible interactions with his cancer chemotherapy regimen that were not clearly defined.
Topics: Adolescent; Combined Modality Therapy; Electroconvulsive Therapy; Humans; Male; Paranoid Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma
PubMed: 8646273
DOI: 10.3109/10401239509149040 -
Current Hematologic Malignancy Reports Jul 2009Allogeneic hematopoietic stem cell transplantation (alloHCT) is the single most potent treatment modality to prevent relapse in adults with acute lymphocytic leukemia,... (Review)
Review
Allogeneic hematopoietic stem cell transplantation (alloHCT) is the single most potent treatment modality to prevent relapse in adults with acute lymphocytic leukemia, but its optimal use and timing remains a matter of intense debate and research. There is general agreement that patients with clinical features of high risk for relapse should undergo alloHCT in first complete remission. However, newer studies suggest that even patients without these risk factors may benefit. Monitoring of minimal residual disease may improve risk stratification and may complement or replace conventional risk features. Prognosis in relapsed and refractory patients is dismal, and alloHCT should be performed as soon as possible. AlloHCT also offers the only reasonable chance for cure in Philadelphia chromosome-positive acute lymphocytic leukemia; the role of imatinib is not yet clearly defined. Recent developments in unrelated-donor transplantation and reduced-intensity conditioning allow the beneficial effects of alloHCT to reach a considerably wider patient population.
Topics: Adult; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Risk Assessment; Time Factors; Transplantation, Homologous; Treatment Outcome
PubMed: 20425427
DOI: 10.1007/s11899-009-0020-7 -
The Journal of Pediatrics Jul 2009
Topics: Antineoplastic Agents; Child; Humans; Hyperglycemia; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Severity of Illness Index
PubMed: 19559280
DOI: 10.1016/j.jpeds.2009.05.020 -
Cancer Biology & Therapy Jun 2020Metastasis in the pineal region is a rare condition. To best of our knowledge, there is no case report of isolated pineal metastasis secondary to acute lymphocytic...
Metastasis in the pineal region is a rare condition. To best of our knowledge, there is no case report of isolated pineal metastasis secondary to acute lymphocytic leukemia (ALL). The aim of this study is to show the pineal gland involvement of ALL in a case for the first time in the literature. A 25-year-old male patient diagnosed with ALL 2 years ago presented with headache and visual impairment. Brain magnetic resonance imaging (MRI) revealed a well-defined solid lesion which was revealed intensive enhancement after contrast. On diffusion-weighted images, the lesion showed significant diffusion restriction. Three months after therapy, control MRI demonstrated a completely resorbed pineal lesion. The pineal region may be a possible site of metastasis and involvement due to the absence of a blood-brain barrier, and should not be overlooked in patients with not only solid cancers but also ALL.
Topics: Adult; Humans; Male; Pinealoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis
PubMed: 32208886
DOI: 10.1080/15384047.2020.1735605 -
Cancer Genetics and Cytogenetics Aug 1992Trisomy 4 has been identified previously as a chromosome abnormality associated with acute nonlymphocytic leukemia (ANLL) with myelomonocytic lineage and in... (Review)
Review
Trisomy 4 has been identified previously as a chromosome abnormality associated with acute nonlymphocytic leukemia (ANLL) with myelomonocytic lineage and in myelodysplastic syndromes (MDS). We report a case of acute lymphocytic leukemia (ALL) (French-American-British, FAB L1) in a 42-year-old Japanese man, with trisomy 4 as the sole chromosomal anomaly. Immunophenotypically, the leukemic blasts demonstrated reactivity with CD2, CD5, and CD7 and indicated on early stage of T cell.
Topics: Adult; Antigens, CD; Chromosomes, Human, Pair 4; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Trisomy
PubMed: 1521241
DOI: 10.1016/0165-4608(92)90045-a -
Journal of Clinical Microbiology Feb 2020
Topics: Child; Child, Preschool; Dermatomycoses; Humans; Male; Mucormycosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhizopus
PubMed: 32094119
DOI: 10.1128/JCM.00787-19 -
Bone Marrow Transplantation Jan 1989Developing improved therapy for the one-third or more of patients who can be expected to relapse after initial treatment for acute lymphoblastic leukemia would be less... (Review)
Review
Developing improved therapy for the one-third or more of patients who can be expected to relapse after initial treatment for acute lymphoblastic leukemia would be less difficult if one could identify potential failures unequivocally at diagnosis. Subgroups of patients who should be considered candidates for highly experimental therapy include infants (less than 1 year of age), patients with the Philadelphia chromosome and perhaps patients with B-cell leukemia. The most important factor that determines the success of therapy after relapse is the length of the patient's initial remission. We recommend bone marrow transplantation for children whose first remission did not exceed 18 months. For all others, it appears that intensive chemotherapy affords as great a potential for cure as one could expect from transplantation. We favor intensive chemotherapy over transplantation in cases of late bone marrow relapse (greater than 18 months), because of the currently high peritransplantation mortality rate. It is not clear whether either modality will be adequate for patients relapsing on contemporary treatment programs.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Drug Resistance; Humans; Infant; Meningeal Neoplasms; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis
PubMed: 2653524
DOI: No ID Found -
Pediatric Blood & Cancer Sep 2005Osteopathy is one of the common initial symptoms of acute lymphocytic leukemia (ALL) in children and adolescents, but multiple osteolysis accompanied by hypercalcemia is... (Review)
Review
Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature.
BACKGROUND
Osteopathy is one of the common initial symptoms of acute lymphocytic leukemia (ALL) in children and adolescents, but multiple osteolysis accompanied by hypercalcemia is rarely observed.
PROCEDURE
We treated a 14-year-old female who had multiple osteolytic lesions and hypercalcemia at initial onset of ALL. In this case we examined some humoral factors, which are known to associate with hypercalcemia in malignancies.
RESULTS
Parathyroid hormone-related peptide (PTHrP) was elevated in serum, and reverse transcriptase-polymerase chain reaction and immunohistochemistry revealed that the lymphoblasts produced PTHrP directly. Other humoral factors related to hypercalcemia were not detected. ALL relapsed in the bone marrow 3 months after achieving complete remission, and hypercalcemia and elevation of serum PTHrP were also observed. A second remission could not be achieved and hypercalcemia continued. The patient received allogeneic bone marrow transplantation. The serum calcium level became normal after the conditioning therapy. Before engraftment, however, the patient died of infection.
CONCLUSIONS
The present case suggests that blast-producing PTHrP might be associated with multiple osteolytic lesions and hypercalcemia. PTHrP expressed in the lymphoblasts may, in itself, confer a survival advantage to lymphoblasts and contribute to the refractory nature of the disease.
Topics: Adolescent; Fatal Outcome; Female; Humans; Hypercalcemia; Osteolysis; Parathyroid Hormone-Related Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence
PubMed: 15700250
DOI: 10.1002/pbc.20357 -
Hematology/oncology Clinics of North... Feb 2001With effective CNS prophylaxis, most adults with ALL may remain free of CNS leukemia. Several combinations of IT chemotherapy, high-dose systemic chemotherapy, and... (Review)
Review
With effective CNS prophylaxis, most adults with ALL may remain free of CNS leukemia. Several combinations of IT chemotherapy, high-dose systemic chemotherapy, and cranial irradiation have been used with varying results. Excellent prophylaxis can be achieved without cranial irradiation, and in view of the potential acute and long-term toxicity of radiation, these methods may be preferable. A prophylactic approach tailored to the risk of CNS leukemia was shown to be valuable in childhood ALL and in at least one adult study. Further studies should focus on defining risk groups for CNS leukemia and designing effective prophylaxis for each group. More research is needed to define the intensity and duration of treatment and the role of cranial irradiation in the treatment of isolated CNS relapses.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Child; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Humans; Injections, Spinal; Leukemic Infiltration; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Outcome
PubMed: 11253605
DOI: 10.1016/s0889-8588(05)70203-3 -
Hematology. American Society of... 2007Significant advances in the treatment of Philadelephia chromosome (Ph)- or BCR-ABL-positive acute lymphocytic leukemia (ALL) have been made since the discovery of the... (Review)
Review
Significant advances in the treatment of Philadelephia chromosome (Ph)- or BCR-ABL-positive acute lymphocytic leukemia (ALL) have been made since the discovery of the selective ABL tyrosine kinase inhibitors (TKIs). Whereas the outcome with standard chemotherapy was previously dismal, incorporation of imatinib mesylate into frontline therapy has improved relapse-free and overall survival. The benefit of imatinib extends particularly to instances where allogeneic stem cell transplantation in first complete remission is prohibited by older age, comorbidities, or lack of a suitable donor. However, the emergence of resistance to imatinib presents new therapeutic challenges. The development of novel TKIs with enhanced inhibitory potency against ABL and other kinases may further improve on the results observed with imatinib. Optimal use of these novel agents in the treatment schema of Ph(+) ALL will be paramount in ensuring continued success in the eradication of this disease. Herein, the new approaches to the management of Ph(+) ALL are reviewed.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation
PubMed: 18024662
DOI: 10.1182/asheducation-2007.1.435